Home > Report on the risk assessment of N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4-fluoroisobutyrylfentanyl 4F-iBF), in the framework of the Council Decision on new psychoactive substances. Risk Assessments.

European Monitoring Centre for Drugs and Drug Addiction. (2018) Report on the risk assessment of N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4-fluoroisobutyrylfentanyl 4F-iBF), in the framework of the Council Decision on new psychoactive substances. Risk Assessments. Luxembourg: Publications Office of the European Union. 55 p.

[img]
Preview
PDF (Risk assessment 4F-iBF) - Published Version
1MB

This publication presents the data and findings of the risk assessment on N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place 4F-iBF in Schedule I of the Single Convention on Narcotic Drugs of 1961 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.

Item Type:Evidence resource
Publication Type:Report
Drug Type:New psychoactive substance
Intervention Type:AOD disorder harm reduction
Date:July 2018
Pages:55 p.
Publisher:Publications Office of the European Union
Corporate Creators:European Monitoring Centre for Drugs and Drug Addiction
Place of Publication:Luxembourg
EndNote:View
Accession Number:HRB (Electronic Only)
Subjects:B Drugs and alcohol substances > New (novel) psychoactive substances
J Health care, prevention and rehabilitation > Risk and needs assessment > Risk assessment
MM-MO Crime and law > Organised crime
VA Geographic area > International aspects

Repository Staff Only: item control page